Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 10:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 91 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Buprenorphine Injection Clear all
Completed Phase 2 Interventional Results available

Phase II Pharmacokinetics Study of CAM2038

NCT02710526
View directory record Official record
Conditions
Opioid Use Disorder, Chronic Pain
Interventions
CAM2038
Drug
Lead sponsor
Braeburn Pharmaceuticals
Industry
Eligibility
19 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
3
States / cities
Birmingham, Alabama • Berlin, New Jersey • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 30, 2020 · Synced Oct 17, 2026, 10:34 PM EDT
Completed Phase 4 Interventional Results available

Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users

NCT04995029
View directory record Official record
Conditions
Moderate to Severe Opioid-use Disorder
Interventions
Transmucosal Buprenorphine, Extended-release Buprenorphine
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years and older
Enrollment
785 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
28
States / cities
Garden Grove, California • Panorama City, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 17, 2026, 10:34 PM EDT
Completed Phase 1Phase 2 Interventional Results available

An Open-Label Pilot Study of Sublocade as Treatment for Opiate Use Disorder

NCT03861338
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Sublocade
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Oct 17, 2026, 10:34 PM EDT
Completed Phase 4 Interventional Results available

Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry

NCT01999946
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders
Interventions
Extended-Release Naltrexone
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 99 Years
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 25, 2021 · Synced Oct 17, 2026, 10:34 PM EDT
Completed Phase 4 Interventional Results available

Addition of Buprenorphine to Paracervical Block for Pain Control During Osmotic Dilator Insertion

NCT04254081
View directory record Official record
Conditions
Procedural Pain, Buprenorphine, Adjuvants, Anesthesia, Dilation and Evacuation, Analgesics
Interventions
Buprenorphine 0.15 MG, Lidocaine 1% Injectable Solution
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 17, 2026, 10:34 PM EDT
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

NOTRE: Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral Settings

NCT06854029
View directory record Official record
Conditions
HIV Infections, Opioid Use Disorder, Incarceration; Lens
Interventions
Cabotegravir Injection, Cabotegravir Pill, Buprenorphine injection, Buprenorphine Pill
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 17, 2026, 10:34 PM EDT
Completed Phase 2 Interventional

Comparison of Buprenorphine to Morphine in Treatment of Neonatal Abstinence Syndrome (NAS)

NCT01708707
View directory record Official record
Conditions
Neonatal Abstinence Syndrome, Neonatal Withdrawal Syndrome
Interventions
Buprenorphine, Morphine Sulfate
Drug
Lead sponsor
Pediatrix
Other
Eligibility
Up to 1 Year
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Oct 17, 2026, 10:34 PM EDT
Not yet recruiting Phase 4 Interventional

Comparing Outpatient Treatment Retention Among Individuals Using Fentanyl Randomized to Low-dose and Direct-to-inject Buprenorphine Initiation

NCT07469501
View directory record Official record
Conditions
Opioid Use Disorder, Fentanyl
Interventions
Injectable buprenorphine, Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets)
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 17, 2026, 10:34 PM EDT
Recruiting Phase 4 Interventional

Assessing Optimal XRB Initiation Points in Jail

NCT06051890
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Extended-Release Buprenorphine (XRB), Sublingual Buprenorphine (SLB)
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Boston, Massachusetts • Springfield, Massachusetts • New Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 17, 2026, 10:34 PM EDT
Completed Not applicable Interventional

Pilot Test of a Community-based Buprenorphine Treatment Intervention

NCT01761110
View directory record Official record
Conditions
Opioid Dependence, Injection Drug Use
Interventions
Community-based buprenorphine treatment (CBBT) intervention
Behavioral
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Oct 17, 2026, 10:34 PM EDT
Completed Phase 2Phase 3 Interventional

EXHIT ENTRE Comparative Effectiveness Trial

NCT04345718
View directory record Official record
Conditions
Substance Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe
Interventions
Extended Release Buprenorphine, Treatment as Usual
Drug
Lead sponsor
Gavin Bart
Other
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 17, 2026, 10:34 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Interscalene Block With Liposomal Bupivacaine vs. Interscalene Block With Bupivacaine and Adjuvants

NCT03845894
View directory record Official record
Conditions
Shoulder Arthroplasty
Interventions
Liposomal bupivacaine, Bupivacaine with adjuvants
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 17, 2026, 10:34 PM EDT
Not listed Not applicable Interventional

Serratus Anterior Plane Block With and Without Adjuvants in Video-assisted Thoracoscopy

NCT05090761
View directory record Official record
Conditions
Post Operative Pain, Acute
Interventions
Bupivacaine 0.25% Injectable Solution, Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 150 mg, Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 150 mg, Buprenorphine 300 mcg
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 100 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Pontiac, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 17, 2026, 10:34 PM EDT
Terminated No phase listed Observational

An Observational Study of Environmental and Socioeconomic Factors in Opioid Recovery - Long Term

NCT04577144
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Online survey only
Other
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 7, 2022 · Synced Oct 17, 2026, 10:34 PM EDT
Recruiting Phase 4 Interventional

Injectable Buprenorphine in Prison: A Preference Trial

NCT06880718
View directory record Official record
Conditions
Opioid Use Disorder, Incarceration, Medications for Opioid Use Disorder, Buprenorphine
Interventions
Brixadi (Injectable Buprenorphine), Sublocade
Drug
Lead sponsor
Lifespan
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Cranston, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 17, 2026, 10:34 PM EDT
Recruiting Early Phase 1 Interventional

A Clinical Trial Comparing Buprenorphine Formulations for High Potency Synthetic Opioid Use

NCT06726200
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Buprenorphine + naloxone (Suboxone), Buprenorphine Injection
Drug
Lead sponsor
Rachel R. Luba
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 17, 2026, 10:34 PM EDT
Recruiting Phase 2 Interventional

Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

NCT06651177
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe
Interventions
Tirzepatide, Placebo
Drug · Other
Lead sponsor
T. John Winhusen, PhD
Other
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
9
States / cities
Jacksonville, Florida • Tampa, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 17, 2026, 10:34 PM EDT
Withdrawn Phase 4 Interventional

Assessing Optimal XR-Buprenorphine Initiation Points in Jail

NCT05481112
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Extended-Release Buprenorphine Injection
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 29, 2024 · Synced Oct 17, 2026, 10:34 PM EDT
Completed No phase listed Observational Results available

Evaluation of Long-term Buprenorphine Plasma Exposure

NCT03752528
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Blood sample collection, Urine sample collection
Diagnostic Test
Lead sponsor
Indivior Inc.
Industry
Eligibility
Not listed
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
11
States / cities
Hamilton, Alabama • Tampa, Florida • Prairie Village, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2020 · Synced Oct 17, 2026, 10:34 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Improving Treatment Outcomes for Prescription Opioid Dependence

NCT02543944
View directory record Official record
Conditions
Drug Dependence
Interventions
Gabapentin, Buprenorphine, Clonidine, Naltrexone (oral), Naltrexone (depot), Placebo
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Oct 17, 2026, 10:34 PM EDT
Not yet recruiting Phase 3 Interventional

An Artificial Intelligence Driven Approach to Optimize Patient Selection for a Transitional Pain Service

NCT07296770
View directory record Official record
Conditions
Postsurgical Pain Management, Postsurgical Pain, Chronic, Opioid Use After Surgery
Interventions
TPS-Select, Pharmacologic Pain Management, Interventional Pain Procedures, Psychological Management and Pain Education, Physical Therapy
Device · Drug · Procedure + 1 more
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 17, 2026, 10:34 PM EDT
Completed No phase listed Observational Results available

Hepatitis C Treatment to Prevent HIV, Initiate Opioid Substitution Therapy, and Reduce Risky Behavior

NCT03221309
View directory record Official record
Conditions
HCV, Buprenorphine, PreP
Interventions
Evaluate model of care for HCV-infected adults with on-going opioid misuse
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Batlimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 17, 2026, 10:34 PM EDT
Completed Phase 3 Interventional Results available

Long-Term Safety Study of Buprenorphine (CAM2038) in Adult Outpatients With Opioid Use Disorder

NCT02672111
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
CAM2038 q1w or q4w exposure to SL BPN/NX, CAM2038 q1w or q4w new to BPN treatment
Drug
Lead sponsor
Braeburn Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
10
States / cities
Birmingham, Alabama • Haleyville, Alabama • Hamilton, Alabama + 7 more
Source: ClinicalTrials.gov public record
Updated May 15, 2020 · Synced Oct 17, 2026, 10:34 PM EDT
Completed Phase 2 Interventional Results available

Extended-Release Buprenorphine vs. Sublingual Buprenorphine for the Treatment of Opioid Use Disorder

NCT04352166
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
extended-release buprenorphine (BXR), sublingual buprenorphine (BSL)
Drug
Lead sponsor
Frances R Levin
Other
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 17, 2026, 10:34 PM EDT